The CD44v6-negative phenotype in high-grade uterine carcinomas correlates with serous histologic subtype

Modern Pathology

Volumn 11, Issue 2, 1998, Pages 194-199

  Soslow, Robert A ^a   Shen, Peter U Fu ^a   Isacson, Christina ^a   Chung, Marilda H ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

CD44; Endometrioid carcinoma; Uterine serous carcinoma

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; UTERUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PHENOTYPE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 0031939782     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 1990;39:266-71.
2. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 100 cases with emphasis on the prognostic significance of associated endometrial carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
3. Lee KR. Recurrence in noninvasive endometrial carcinoma. Am J Surg Pathol 1991;15:965-73.
4. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990;3:120-8.
5. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
6. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
7. Ambros RA, Sheehan CE, Kallakury BVS, Ross JS, Malfetano J, Paunovich E, et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996;9:1165-9.
8. Shen P, Chung M, Isacson C, Soslow RA. Inverse immunohistochemical expression of p53 and MDM-2 in uterine serous carcinoma versus high-grade endometrioid carcinoma suggests different pathogenetic pathways [abstract]. Mod Pathol 1997;10:109A.
9. Miyake K, Underhill CB, Lesley I, Kincade PW. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 1990;172:69-75.
10. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80 lymphocyte homing receptor molecule augment human peripheral blood T-cell activation. J Immunol 1990;144:7-15.
11. Jalkanen ST, Bargatze RF, Herron LR, Butcher EC. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 1986;16:1195-202.
12. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. J Cell Biol 1991;10:343-8.
13. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc natl Acad Sci U S A 1992;89:12160-4.
14. Jackson DG, Buckley J, Bell JI. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 1992;267:4732-9.
15. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;50:4754-6.
16. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 1989; 109:927-37.
17. Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 1995;153:2025-8.
18. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995;89:81-7.
19. Gunthert U, Stauder R, Mayer B, Terpe HJ, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995;24:19-42.
20. Horst E, Meijer CJL, Radaszkiewicz T, Ossekoppele GJ, van Krieken JHJM, Pals ST. Adhesion molecules in the prognosis of diffuse large cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1(CD54). Leukemia 1990;4:595-9.
21. Kuppner MC, Meir EV, Gauthier T, Hamou MF, Detribolet N. Differential expression of the CD44 molecule in human brain tumours. Int J Cancer 1992;50:572-7.
22. Terpe HJ, Koopmann R, Imhof B, Gunthert U. Expression of integrins and CD44 in non-Hodgkin's lymphomas: CD44 variants are preferentially expressed in high-grade malignant lymphomas. J Pathol 1994;174:89-100.
23. Tempfer C, Gitsch G, Haeusler G, Reinthaller A, Koelbl H, Kainz C. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Cancer 1996;78:273-7.
24. Washington K, Gottfried MR, Telen MJ. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 1994;25:1043-9.
25. Mayer B, Jauch KW, Gunthert U, Figdor GC, Schildberg FW, Funke I, et al. De novo expression of CD44 and survival in gastric cancer. Lancet 1993;342:1019-22.
26. Miwa T, Watanabe A, Yamada Y, Shino Y, Yamada T, Yamashita J, et al. Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript. Cancer 1996;77:25-9.
27. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, et al. Expression of CD44 isoforms in renal cell tumors: positive correlation to tumor differentiation. Am J Pathol 1996;148:453-63.
28. Mulder J-WR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
29. Jackson PA, Green MA, Pouli A, Hubbard R, Marks CG, Cook MG. Relation between stage, grade, proliferation, and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. J Clin Pathol 1995;48:1098-101.
30. Ishii S, Ford R, Thomas P, Nachman A, Steele G. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg Oncol 1993;2:255-64.
31. Nagasaka S, Tanabe KK, Bruner JM, Saya H, Sawaya RE, Morrison RS. Alternative RNA splicing of the hyaluronic acid receptor CD44 in the normal human brain and in brain tumors. J Neurosurg 1995;82:858-63.
32. Ariza A, Lopez D, Mate JL, Isamat M, Musulen E, Pujol M, et al. Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum Pathol 1995;26:1144-7.
33. Schumacher U, Horny HP, Horst HA, Herrlich P, Kaiserling E. A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Eur J Surg Oncol 1996;22:259-61.
34. Dall P, Hekele A, Ikenberg H, Goppinger A, Bauknecht T, Pfleiderer A, et al. Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Int J Cancer 1996;69:79-85.
35. Dommann SN, Ziegler T, Dommann-Schener CC, Meyer J, Panizzon R, Burg G. CD44v6 is a marker for systemic spread in cutaneous T-cell lymphomas: a comparative study between nodal and cutaneous lymphomas. J Cut Pathol 1995; 22:407-12.
36. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential source. Anticancer Res 1995;15: 1191-8.
37. Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I, et al. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 1994;54:3922-8.
38. Hudson DL, Speight PM, Watt FM. Altered expression of CD44 isoforms in squamous cell carcinomas and cell lines derived from them. Int J Cancer 1996;66:457-63.
39. Seelentag WK, Gunthert U, Saremaslani P, Futo E, Pfaltz M, Heitz PU, et al. CD44 standard and variant isoform expression in human epidermal skin tumors is not correlated with tumor aggressiveness but down-regulated during proliferation and tumor dedifferentiation. Int J Cancer 1996;69:218-24.
40. Terpe HJ, Christiansen H, Gonzales M, Berthold F, Lampert F. Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Eur J Cancer 1995;31A: 549-52.
41. Spafford MF, Koeppe J, Pan Z, Arcer PG, Meyers AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996;122:627-32.
42. Piffko J, Bankfalvi A, Klauke K, Dreier R, Joos U, Bocker W, et al. Unaltered strong immunohistochemical expression of CD44-v6 and -v5 isoforms during development and progression of oral squamous cell carcinomas. J Oral Pathol Med 1996;25:502-6.
43. Teyssier JR, Couillin P, Benard J, Ravisse N, Ulrich E, Cornillet P. A multidrug-resistant ovarian carcinoma cell line with a malignant suppressed phenotype is a CD44 gene expression defective mutant. Cancer Genet Cytogenet 1992; 60:14-9.
44. Uhl-Steidl M, Muller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, et al. Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology 1995;52:400-6.
45. Behzad F, Seif MW, Campbell S, Apilin JD. Expression of two isoforms of CD44 in human endometrium. Biol Reprod 1994; 151:739-47.
46. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. International histological classification and histologic typing of female genital tract tumors. Berlin: Springer-Verlag; 1994.
47. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
48. Creasman WT. FIGO stages: 1988 revisions. Gynecol Oncol 1989;35:125-7.
49. Castella E, Ariza A, Fernandez-Vasalo A, Roca X, Ojanguren I. Expression of CD44H and CD44v3 in normal oesophagus, Barrett mucosa, and oesophageal carcinoma. Int J Clin Pathol 1996;49:489-92.
50. Sloman A, D'Amico F, Yousem SA. Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung: an immunohistochemical study. Arch Pathol Lab Med 1996;120:465-72.
51. Seiter S, Tilgen W, Herrmann K, Schadendorf D, Patzelt E, Moller P, et al. Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch 1996;28:141-9.
52. Mathew J, Hines IE, Obafunwa JO, Burr AW, Toole K, Burt AD. CD44 is expressed in hepatocellular carcinomas showing vascular invasion. J Pathol 1996;179:74-9.
53. Yamaguchi A, Saito M, Gio T, Iida A, Takeuchi K, Hirose K, et al. Expression of CD44 variant exons 8-10 in gastric cancer, Jpn J Cancer Res 1995;86:1166-71.
54. Kainz C, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A, et al. Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol 1995;57:383-7.